SAM
CTKB icon

Smartleaf Asset Management’s Cytek Biosciences CTKB Stock Holding History

Smartleaf Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-127
Closed -$640 – 3541
2025
Q4 		$640 Buy
+127
New +$590 ﹤0.01% 3234
2025
Q2 		– Sell
-361
Closed -$1.44K – 2778
2025
Q1 		$1.44K Sell
361
-552
-60% -$2.86K ﹤0.01% 2543
2024
Q4 		$5.98K Sell
913
-237
-21% -$1.41K ﹤0.01% 2183
2024
Q3 		$6.2K Buy
1,150
+624
+119% +$3.54K ﹤0.01% 2022
2024
Q2 		$2.89K Buy
+526
New +$3.16K ﹤0.01% 2070

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Smartleaf Asset Management's CTKB Position: Q1 2026 in Review

Smartleaf Asset Management sold out of Cytek Biosciences (CTKB) in Q1 2026, closing a stake of 127 shares — an estimated $640 sold.

Smartleaf Asset Management first reported a position in CTKB in Q2 2024 and held it in 5 quarters. The position peaked at $6.2K in Q3 2024. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Smartleaf Asset Management reported no remaining Cytek Biosciences position as of Q1 2026 after selling out during the quarter.
  • Smartleaf Asset Management sold 127 Cytek Biosciences shares in Q1 2026, an estimated $640.
  • Smartleaf Asset Management first reported a position in Cytek Biosciences in Q2 2024 and held it in 5 quarters.
  • Smartleaf Asset Management's Cytek Biosciences position peaked at $6.2K in Q3 2024.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.